
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is a leading medical technology company with FDA-approved products for organ transplantation and a potential for clinical trial-driven growth. While the company may face operating expenses and competition challenges, its strong performance in recent years and expansion efforts position it well for continued success. Surgeons have expressed positive views on its innovative products, although they have raised concerns about potential competition in the market.
Bears say
TransMedics Group is facing declining share count estimates, leading to a decrease in estimated EPS for fiscal year 2026 and 2027. Additionally, the stock is currently trading below its 2-year and 5-year averages, indicating potential undervaluation. The company is facing competition from XVIVO in the organ preservation market, and its potential entry into the organ procurement market faces opposition and potential challenges. Overall, TransMedics Group is facing financial and market challenges that could impact its future growth potential.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares